Bempedoic Acid in Secondary Prevention

Idine Mousavi; Vijay Nambi; Layla A Abushamat; Sadeer G Al-Kindi; Michael D Shapiro; Laurence Sperling; Salim S Virani; Abdul Mannan Khan Minhas

doi:10.1016/j.ajpc.2024.100715

Bempedoic Acid in Secondary Prevention

Am J Prev Cardiol. 2024 Aug 6:19:100715. doi: 10.1016/j.ajpc.2024.100715. eCollection 2024 Sep.

Authors

Idine Mousavi¹, Vijay Nambi^{1

2

3}, Layla A Abushamat^{1

2}, Sadeer G Al-Kindi⁴, Michael D Shapiro⁵, Laurence Sperling⁶, Salim S Virani^{1

7

8}, Abdul Mannan Khan Minhas^{1

2}

Affiliations

¹ Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
² Division of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
³ Section of Cardiology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas.
⁴ Department of Cardiology, Houston Methodist Hospital, TX, USA.
⁵ Section on Cardiovascular Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
⁶ Division of Cardiology, Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine, Atlanta, GA, USA.
⁷ Aga Khan University, Karachi, Pakistan.
⁸ Baylor College of Medicine and Texas Heart Institute, Houston, TX, USA.

Abstract

•Bempedoic acid has been shown to reduce major adverse cardiovascular outcomes in patients unable to take statins due to statin-associated side effects.•Analysis of CLEAR Outcomes trial data reveals possible differences in baseline characteristics between the primary and secondary prevention subgroups.•Further research is needed to optimize use of bempedoic acid and clarify its impact on cardiovascular outcomes in diverse patient populations.